IFN signaling: How a non-canonical model led to the development of IFN mimetics

Frontiers in Immunology

Volumn 4, Issue JUL, 2013, Pages

  Johnson, Howard M ^a   Noon Song, Ezra Neptune ^a   Dabelic, Rea ^b   Ahmed, Chulbul M ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Columbia University ^*  (United States)

Author keywords

Cytokines; Interferon mimetics; Interferon receptor; Interferon signaling; JAK STAT signaling

Indexed keywords

ALPHA1 INTERFERON; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; JANUS KINASE; STEROID HORMONE;

APOPTOSIS; BONE MARROW SUPPRESSION; ENDOCYTOSIS; EPIGENETICS; GENE ACTIVATION; HUMAN; IMMUNIZATION; NEOPLASM; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TOXICITY;

EID: 84883736124     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00202     Document Type: Review

References (84)

1. Brivanlou AH, Darnell JE Jr. Signal transduction and the control of gene expression. Science (2002) 295:813-8. doi:10.1126/science.1066355
2. Liao HJ, Carpenter G. Role of the Sec61 translocon in EGF receptor trafficking to the nucleus and gene expression. Mol Biol Cell (2007) 18:1064-72. doi:10.1091/mbc. E06-09-0802
3. Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 13:722-8. doi:10.1038/ni.2366
4. Swanson SM, Kopchick JJ. Nuclear localization of growth hormone receptor: another age of discovery for cytokine action?. Sci STKE (2007) 2007:e69. doi:10.1126/stke.4152007pe69
5. Brooks AJ, Wooh JW, Tunny KA, Waters MJ. Growth hormone receptor; mechanism of action. Int J Biochem Cell Biol (2008) 40:1984-9. doi:10.1016/j.biocel.2007.07.008
6. Cortes-Reynosa P, Robledo T, Salazar EP. Epidermal growth factor promotes epidermal growth factor receptor nuclear accumulation by a pathway dependent on cytoskeleton integrity in human breast cancer cells. Arch Med Res (2009) 40:331-8. doi:10.1016/j.arcmed.2009.06.007
7. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNgamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev (2008) 19:383-94. doi:10.1016/j.cytogfr.2008.08.004
8. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature (2009) 461:819-22. doi:10.1038/nature08448
9. Subramaniam PS, Torres BA, Johnson HM. So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors. Cytokine (2001) 15:175-87. doi:10.1006/cyto.2001.0905
10. Johnson HM, Subramaniam PS, Olsnes S, Jans DA. Trafficking and signaling pathways of nuclear localizing protein ligands and their receptors. Bioessays (2004) 26:993-1004. doi:10.1002/bies.20086
11. Johnson HM, Noon-Song EN, Kemppainen K, Ahmed CM. Steroid-like signalling by interferons: making sense of specific gene activation by cytokines. Biochem J (2012) 443:329-38. doi:10.1042/BJ20112187
12. O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med (2013) 368:161-70. doi:10.1056/NEJMra1202117
13. Subramaniam PS, Khan SA, Pontzer CH, Johnson HM. Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Proc Natl Acad Sci U S A (1995) 92:12270-4. doi:10.1073/pnas.92.26.12270
14. Burks J. Interferon-beta 1b for multiple sclerosis. Expert Rev Neurother (2005) 5:153-64. doi:10.1586/14737175.5.2.153
15. Ahmed CM, Johnson HM. IFN-gamma and its receptor subunit IFNGR1 are recruited to the IFN-gamma-activated sequence element at the promoter site of IFNgamma- activated genes: evidence of transactivational activity in IFNGR1. J Immunol (2006) 177:315-21.
16. Noon-Song EN, Ahmed CM, Dabelic R, Canton J, Johnson HM. Controlling nuclear JAKs and STATs for specific gene activation by IFNgamma. Biochem Biophys Res Commun (2011) 410:648-53. doi:10.1016/j.bbrc.2011.06.047
17. Ahmed CM, Noon-Song EN, Kemppainen K, Pascalli MP, Johnson HM. Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy. J Neuroimmunol (2013) 254:101-9. doi:10.1016/j.jneuroim.2012.10.006
18. Szente BE, Johnson HM. Binding of IFN gamma and its C-terminal peptide to a cytoplasmic domain of its receptor that is essential for function. Biochem Biophys Res Commun (1994) 201:215-21. doi:10.1006/bbrc.1994.1691
19. Albericio F, Kruger HG. Therapeutic peptides. Future Med Chem (2012) 4:1527-31. doi:10.4155/fmc.12.94
20. Pestka S. The interferon receptors. Semin Oncol (1997) 24:S9-18.
21. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604
22. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, and Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell (1998) 93:827-39. doi:10.1016/S0092-8674(00)81443-9
23. Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, Lundell DJ, et al. Signaling by covalent heterodimers of interferon-gamma. Evidence for onesided signaling in the active tetrameric receptor complex. J Biol Chem (2000) 275:22995-3004. doi:10.1074/jbc. M909607199
24. Landar A, Curry B, Parker MH, Digiacomo R, Indelicato SR, Nagabhushan TL, et al. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma. J Mol Biol (2000) 299:169-79. doi:10.1006/jmbi.2000.3734
25. Watford WT, Moriguchi M, Morinobu A, and O'Shea JJ. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev (2003) 14:361-8. doi:10.1016/S1359-6101(03)00043-1
26. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol (2011) 12:247-54. doi:10.1038/ni.1995
27. Lobie PE, Ronsin B, Silvennoinen O, Haldosen LA, Norstedt G, Morel G. Constitutive nuclear localization of Janus kinases 1 and 2. Endocrinology (1996) 137:4037-45. doi:10.1210/en.137.9.4037
28. Ragimbeau J, Dondi E, Vasserot A, Romero P, Uze G, Pellegrini S. The receptor interaction region of Tyk2 contains a motif required for its nuclear localization. J Biol Chem (2001) 276:30812-8. doi:10.1074/jbc. M103559200
29. Hao A, Novotny-Diermayr V, Bian W, Lin B, Lim CP, Jing N, et al. The LIM/homeodomain protein Islet1 recruits Janus tyrosine kinases and signal transducer and activator of transcription 3 and stimulates their activities. Mol Biol Cell (2005) 16:1569-83. doi:10.1091/mbc. E04-08-0664
30. Nilsson J, Bjursell G, Kannius-Janson M. Nuclear Jak2 and transcription factor NF1-C2: a novel mechanism of prolactin signaling in mammary epithelial cells. Mol Cell Biol (2006) 26:5663-74. doi:10.1128/MCB.02095-05
31. Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM, et al. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol (2011) 13:13-21. doi:10.1038/ncb2135
32. Zouein FA, Duhe RJ, Booz GW. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors (2011) 29:245-52. doi:10.3109/08977194.2011.614949
33. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem (1997) 272:17694-702. doi:10.1074/jbc.272.28.17694
34. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A (2005) 102:18962-7. doi:10.1073/pnas.0509714102
35. Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem (2008) 283:5258-66. doi:10.1074/jbc. M707125200
36. Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX. JAK signaling globally counteracts heterochromatic gene silencing. Nat Genet (2006) 38:1071-6. doi:10.1038/ng1860
37. Rutherford MN, Kumar A, Coulombe B, Skup D, Carver DH, Williams BR. Expression of intracellular interferon constitutively activates ISGF3 and confers resistance to EMC viral infection. J Interferon Cytokine Res (1996) 16:507-10. doi:10.1089/jir.1996.16.507
38. Ahmed CM, Wills KN, Sugarman BJ, Johnson DE, Ramachandra M, Nagabhushan TL, et al. Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice. J Interferon Cytokine Res (2001) 21:399-408. doi:10.1089/107999001750277871
39. Larkin J 3rd, Johnson HM, Subramaniam PS. Differential nuclear localization of the IFNGR-1 and IFNGR-2 subunits of the IFN-gamma receptor complex following activation by IFN-gamma. J Interferon Cytokine Res (2000) 20:565-76. doi:10.1089/10799900050044769
40. Subramaniam PS, Larkin J 3rd, Mujtaba MG, Walter MR, Johnson HM. The COOH-terminal nuclear localization sequence of interferon gamma regulates STAT1 alpha nuclear translocation at an intracellular site. J Cell Sci (2000) 113(Pt 15):2771-81.
41. Ahmed CM, Burkhart MA, Mujtaba MG, Subramaniam PS, Johnson HM. The role of IFNgamma nuclear localization sequence in intracellular function. J Cell Sci (2003) 116:3089-98. doi:10.1242/jcs.00528
42. Szente BE, Subramaniam PS, Johnson HM. Identification of IFN-gamma receptor binding sites for JAK2 and enhancement of binding by IFN-gamma and its Cterminal peptide IFN-gamma(95-133). J Immunol (1995) 155:5617-22.
43. Ahmed CM, Burkhart MA, Subramaniam PS, Mujtaba MG, Johnson HM. Peptide mimetics of gamma interferon possess antiviral properties against vaccinia virus and other viruses in the presence of poxvirus B8R protein. J Virol (2005) 79:5632-9. doi:10.1128/JVI.79.9.5632-5639.2005
44. Berger SL. The complex language of chromatin regulation during transcription. Nature (2007) 447:407-12. doi:10.1038/nature05915
45. Mehta NT, Truax AD, Boyd NH, Greer SF. Early epigenetic events regulate the adaptive immune response gene CIITA. Epigenetics (2011) 6:516-25. doi:10.4161/epi.6.4.14516
46. Ahmed CM, Dabelic R, Martin JP, Jager LD, Haider SM, Johnson HM. Enhancement of antiviral immunity by small molecule antagonist of suppressor of cytokine signaling. J Immunol (2010) 185:1103-13. doi:10.4049/jimmunol.0902895
47. Szente BE, Weiner IJ, Jablonsky MJ, Krishna NR, Torres BA, Johnson HM. Structural requirements for agonist activity of a murine interferon-gamma peptide. J Interferon Cytokine Res (1996) 16:813-7. doi:10.1089/jir.1996.16.813
48. Ahmed CM, Martin JP, Johnson HM. IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses. J Immunol (2007) 178:4576-83.
49. Thiam K, Loing E, Delanoye A, Diesis E, Gras-Masse H, Auriault C, et al. Unrestricted agonist activity on murine and human cells of a lipopeptide derived from IFN-gamma. Biochem Biophys Res Commun (1998) 253:639-47. doi:10.1006/bbrc.1998.9831
50. Moss B. Poxviridae: the viruses and their replication. 3rd ed. In: DM Knipe and PM Howley----- editors. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins (2007). p. 2905-46.
51. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 74:11230-9. doi:10.1128/JVI.74.23.11230-11239.2000
52. Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ, et al. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer (1998) 82:1677-81. doi:10.1002/(SICI)1097-0142(19980501)82:9<1677::AID-CNCR13>3.0.CO;2-1
53. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev (2001) 14:778-809. doi:10.1128/CMR.14.4.778-809.2001
54. Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord (2012) 5:205-20. doi:10.1177/1756285612450936
55. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol (2005) 62:785-92. doi:10.1001/archneur.62.5.785
56. Francis GS, Grumser Y, Alteri E, MicaleffA, O'Brien F, Alsop J, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf (2003) 26:815-27. doi:10.2165/00002018-200326110-00006
57. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell (2011) 146:621-32. doi:10.1016/j.cell.2011.06.048
58. El Behi M, Dubucquoi S, Lefranc D, Zephir H, De Seze J, Vermersch P, et al. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett (2005) 96:11-26. doi:10.1016/j.imlet.2004.07.017
59. Stuve O. Knowns and unknowns in the future of multiple sclerosis treatment. J Neurol Sci (2009) 287(Suppl 1):S30-6. doi:10.1016/S0022-510X(09)71298-5
60. Subramaniam PS, Johnson HM. Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1alpha. J Immunol (2002) 169:1959-69.
61. Sehgal PB, Guo GG, Shah M, Kumar V, Patel K. Cytokine signaling: STATS in plasma membrane rafts. J Biol Chem (2002) 277:12067-74. doi:10.1074/jbc. M200018200
62. Marchetti M, Monier MN, Fradagrada A, Mitchell K, Baychelier F, Eid P, et al. Stat-mediated signaling induced by type I and type II interferons (IFNs) is differentially controlled through lipid microdomain association and clathrin-dependent endocytosis of IFN receptors. Mol Biol Cell (2006) 17:2896-909. doi:10.1091/mbc. E06-01-0076
63. Carpenter G. Nuclear localization and possible functions of receptor tyrosine kinases. Curr Opin Cell Biol (2003) 15:143-8. doi:10.1016/S0955-0674(03)00015-2
64. Wang YN, Hung MC. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci (2012) 2:13. doi:10.1186/2045-3701-2-13
65. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol (2001) 3:802-8. doi:10.1038/ncb0901-802
66. Wang YN, Wang H, Yamaguchi H, Lee HJ, Lee HH, Hung MC. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun (2010) 399:498-504. doi:10.1016/j.bbrc.2010.07.096
67. Wang YN, Yamaguchi H, Huo L, Du Y, Lee HJ, Lee HH, et al. The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem (2010) 285:38720-9. doi:10.1074/jbc. M110.158659
68. Olsnes S, Klingenberg O, Wiedlocha A. Transport of exogenous growth factors and cytokines to the cytosol and to the nucleus. Physiol Rev (2003) 83:163-82.
69. Bryant DM, Stow JL. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic (2005) 6:947-54. doi:10.1111/j.1600-0854.2005.00332.x
70. Stachowiak MK, Maher PA, Stachowiak EK. Integrative nuclear signaling in cell development - a role for FGF receptor-1. DNA Cell Biol (2007) 26:811-26. doi:10.1089/dna.2007.0664
71. Imamura T, Engleka K, Zhan X, Tokita Y, Forough R, Roeder D, et al. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science (1990) 249:1567-70. doi:10.1126/science.1699274
72. Sorensen V, Wiedlocha A, Haugsten EM, Khnykin D, Wesche J, Olsnes S. Different abilities of the four FGFRs to mediate FGF-1 translocation are linked to differences in the receptor C-terminal tail. J Cell Sci (2006) 119:4332-41. doi:10.1242/jcs.03209
73. Zhen Y, Sorensen V, Skjerpen CS, Haugsten EM, Jin Y, Walchli S, et al. Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnalpha1 and Kpnbeta1. Traffic (2012) 13:650-64. doi:10.1111/j.1600-0854.2012.01341.x
74. Stanisic V, Lonard DM, and O'Malley BW. Modulation of steroid hormone receptor activity. Prog Brain Res (2010) 181:153-76. doi:10.1016/S0079-6123(08) 81009-6
75. Vicent GP, Ballare C, Nacht AS, Clausell J, Subtil-Rodriguez A, Quiles I, et al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell (2006) 24:367-81. doi:10.1016/j.molcel.2006.10.011
76. Weigel NL, Moore NL. Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl Recept Signal (2007) 5:e005.
77. Vicent GP, Nacht AS, Zaurin R, Ballare C, Clausell J, Beato M. Minireview: role of kinases and chromatin remodeling in progesterone signaling to chromatin. Mol Endocrinol (2010) 24:2088-98. doi:10.1210/me.2010-0027
78. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res (2005) 65:338-48.
79. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 98:1570-83. doi:10.1002/jcb.20876
80. Hagan CR, Faivre EJ, Lange CA. Scaffolding actions of membrane-associated progesterone receptors. Steroids (2009) 74:568-72. doi:10.1016/j.steroids.2008.12.004
81. Subramaniam PS, Johnson HM. The IFNAR1 subunit of the type I IFN receptor complex contains a functional nuclear localization sequence. FEBS Lett (2004) 578:207-10. doi:10.1016/j.febslet.2004.10.085
82. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res (2011) 31:33-40. doi:10.1089/jir.2010.0100
83. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS ONE (2011) 6:e19605. doi:10.1371/journal.pone.0019605
84. Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI, et al. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res (2011) 71:3720-31. doi:10.1158/0008-5472.CAN-10-307